4.4 Article

Increased HLA-G Expression in Tissue-Infiltrating Cells in Inflammatory Bowel Diseases

Journal

DIGESTIVE DISEASES AND SCIENCES
Volume 66, Issue 8, Pages 2610-2618

Publisher

SPRINGER
DOI: 10.1007/s10620-020-06561-3

Keywords

Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; HLA-G; Inflammatory cells

Funding

  1. Brazilian Research Foundation CNPq [304931/2014-1]
  2. Brazilian Research Foundation CAPES [001]

Ask authors/readers for more resources

This study evaluated intestinal HLA-G expression and sHLA-G levels in CD/UC patients, finding increased HLA-G expression in infiltrating plasma cells/lymphocytes in CD/UC biopsies and higher levels of sHLA-G in lesion areas of surgical specimens from CD/UC patients compared to margins.Higher levels of sHLA-G were observed in UC/CD patients compared to controls, with no difference between the two diseases.
Background Since HLA-G is an immune checkpoint molecule and since Crohn's disease (CD) and ulcerative colitis (UC) exhibit deregulated immune-mediated mechanisms, we aimed to evaluate intestinal HLA-G expression and soluble HLA-G (sHLA-G) levels in CD/UC patients stratified according to the CD phenotype/localization and UC extension. Methods HLA-G tissue expression was assessed by immunohistochemistry in biopsies collected from 151 patients (90 CD, 61 UC) and in surgical resection specimens (28 CD, 12 UC). Surgical material from 24 healthy controls was also assessed. Plasma sHLA-G levels (97 CD, 81 UC, and 120 controls) were evaluated using ELISA. Results HLA-G expression was similarly observed in the intestinal epithelial cells of control and CD/UC specimens. However, in biopsies, the plasma cells/lymphocytes infiltrating the lamina propria in CD/UC presented (1) increased HLA-G expression compared to controls (P < 0.0001), (2) greater cell staining in UC cells than in CD cells irrespective of disease extent (P = 0.0011), and (3) an increased number of infiltrating cells in the inflammatory CD phenotype compared to that in the stenosing and fistulizing phenotypes (P = 0.0407). In surgical specimens, CD/UC patients exhibited higher infiltrating cell HLA-G expression in lesion areas than in margins. sHLA-G levels were higher in UC/CD patients (P < 0.0001) than in controls, but no difference was observed between diseases. Conclusions Increased infiltrating cell HLA-G expression associated with increased sHLA-G levels in CD/UC patients may reflect ongoing host strategies to suppress chronic inflammation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Immunology

Computational and atomistic studies applied to the understanding of the structural and behavioral features of the immune checkpoint HLA-G molecule and gene

Cinthia C. Alves, Thais Arns, Maria L. Oliveira, Philippe Moreau, Dinler A. Antunes, Erick C. Castelli, Celso T. Mendes-Junior, Silvana Giuliatti, Eduardo A. Donadi

Summary: In this study, we utilized computational and atomistic approaches to evaluate the structure and dynamics of HLA-G isoforms, the impact of missense mutations at LILRB1/2 genes, and the differential binding of HIF1 to HREs at the HLA-G gene. We also discovered new findings including the instability of HLA-G6 isoforms, the impact of amino acid exchanges at the intracellular domain on HLA-G binding, and the higher affinity of HREs with a guanine at the third position for HIF1. These results shed light on the functional aspects of HLA-G and provide alternative tools to experimental physical methodologies.

HUMAN IMMUNOLOGY (2023)

Article Immunology

The turning point of COVID-19 severity is associated with a unique circulating neutrophil gene signature

Carlos A. Fuzo, Thais F. C. Fraga-Silva, Sandra R. Maruyama, Victor A. F. Bastos, Luana A. Rogerio, Nayore T. Takamiya, Pedro V. da Silva-Neto, Vinicius E. Pimentel, Diana M. Toro, Malena M. Perez, Jonatan C. S. de Carvalho, Ingryd Carmona-Garcia, Camilla N. S. Oliveira, Augusto M. Degiovani, Fatima M. Ostini, Leticia F. Constant, Alessandro P. de Amorim, Fernando C. Vilar, Marley R. Feitosa, Rogerio S. Parra, Jose J. R. da Rocha, Omar Feres, Gilberto G. Gaspar, Angelina L. Viana, Ana P. M. Fernandes, Isabel K. F. M. Santos, Elisa M. S. Russo, Cristina R. B. Cardoso, Carlos A. Sorgi, Lucia H. Faccioli, Vania L. D. Bonato, Marcelo Dias-Baruffi

Summary: COVID-19 patients exhibit a wide range of clinical manifestations due to the heterogeneity of the host immune response. By analyzing blood transcriptome, demographic data, clinical aspects, and laboratory findings, we identified perturbations in the blood-leukocyte transcriptional profile that are associated with COVID-19 aggravation and stratify patients according to disease severity. These molecular changes involve processes that inhibit lymphocyte activation and promote neutrophil activation, and the central genes of this unique neutrophil signature are S100A9, ANXA3, CEACAM6, VNN1, OLFM4, IL1R2, TCN1, and CD177.

IMMUNOLOGY (2023)

Article Dermatology

Dexamethasone-cyclophosphamide pulse therapy outcomes comparing pemphigus vulgaris and pemphigus foliaceus groups in a Brazilian cohort study

Ludmilla Figueiredo Fontenelle, Roberto Bueno-Filho, Renata Delfino, Giovanna Stefanne Lopes Barbosa, Eduardo Antonio Donadi, Ana Maria Roselino

Summary: DCP/DP treatment showed similar outcomes in PV and PF patients. Earlier initiation of DCP/DP should be considered for PF patients due to longer disease duration.

ANAIS BRASILEIROS DE DERMATOLOGIA (2023)

Letter Immunology

Congenital Zika Virus Syndrome and Autoimmunity: Two Case Reports of Type 1 Diabetes Mellitus

Nivia Maria Rodrigues Arrais, Ricardo Fernando Arrais, Marilia Costa Coelho, Neifi Hassan Saloum Deghaide, Eduardo Antonio Donadi, Claudia Rodrigues Souza Maia, Maria Isabel de Moraes-Pinto

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2023)

Article Virology

The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19

Jonatan C. S. de Carvalho, Pedro V. da Silva-Neto, Diana M. Toro, Carlos A. Fuzo, Viviani Nardini, Vinicius E. Pimentel, Malena M. Perez, Thais F. C. Fraga-Silva, Camilla N. S. Oliveira, Augusto M. Degiovani, Fatima M. Ostini, Marley R. Feitosa, Rogerio S. Parra, Jose J. R. da Rocha, Omar Feres, Fernando C. Vilar, Gilberto G. Gaspar, Isabel K. F. M. Santos, Ana P. M. Fernandes, Sandra R. Maruyama, Elisa M. S. Russo, Vania L. D. Bonato, Cristina R. B. Cardoso, Marcelo Dias-Baruffi, Lucia H. Faccioli, Carlos A. Sorgi

Summary: COVID-19 is associated with immune dysregulation, and glucocorticoids (GCs) have attracted attention for their role in inhibiting pro-inflammatory cytokines. The endocannabinoid (eCB) system also regulates immune response. However, the effect of GCs on the lipid pathway in COVID-19 therapy is still unknown.

VIRUSES-BASEL (2023)

Article Medicine, General & Internal

Access to High-Cost Biological Agents: Perceptions of Brazilian Patients with Inflammatory Bowel Diseases

Rogerio Serafim Parra, Sandro da Costa Ferreira, Vanessa Foresto Machado, Cintia Maura Caseiro Nigro, Jose Joaquim Ribeiro da Rocha, Luiz Ernesto de Almeida Troncon, Omar Feres

Summary: This study aimed to analyze Brazilian patients with inflammatory bowel diseases (IBD) perception regarding access to high-cost drugs in the public health care system. The results showed that most patients were unable to obtain biological drugs within one year. This study highlights the need for improvement in the healthcare system to ensure the correct supply of medication.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Medicine, General & Internal

Leukocytoclastic Vasculitis Secondary to Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases: A Multicenter Retrospective Cohort Study

Rogerio Serafim Parra, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Sergio Figueiredo de Lima Junior, Manoel Alvaro Lins Neto, Terry Rocha de Medeiros, Francesca Maia Faria, Marley Ribeiro Feitosa, Cintia Maura Caseiro Nigro, Omar Feres

Summary: This study presents a case series of vasculitis induced by anti-TNF therapy in patients with inflammatory bowel disease (IBD). Five patients with leukocytoclastic vasculitis (LCV) were identified, all of whom were white, female, and non-smokers. The onset of LCV occurred at an average of 30.8 months after starting biologic therapy, and all patients showed significant improvement after discontinuation of anti-TNF therapy and treatment with oral steroids.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Pharmacology & Pharmacy

Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn's Disease: A Cross-Sectional Multicentric Latin American Study

Leticia Rodrigues de Souza, Daniela Oliveira Magro, Fabio Vieira Teixeira, Rogerio Serafim Parra, Eron Fabio Miranda, Omar Feres, Rogerio Saad-Hossne, Giedre Soares Prates Herrerias, Renato Mitsunori Nisihara, Claudio Saddy Rodrigues Coy, Ligia Yukie Sassaki, Paulo Gustavo Kotze

Summary: Despite some variability in ADA concentrations, higher concentrations are associated with sustained efficacy and low levels can lead to loss of response in CD patients. This study aimed to correlate serum ADA concentrations with clinical and endoscopic activity in CD patients. The results showed no difference in serum ADA concentrations in active or remission CD patients, suggesting no correlation between ADA concentrations and disease activity.

PHARMACEUTICS (2023)

Article Biochemistry & Molecular Biology

Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction-A Prospective Trial

Karoline Soares Garcia, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Luisa Leite Barros, Jane Oba, Carlos Walter Sobrado Junior, Aytan Miranda Sipahi, Olivia Duarte de Castro Alves, Tomas Navarro-Rodriguez, Rogerio Serafim Parra, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Cristina Flores, Andrea Vieira, Christianne Damasceno Arcelino do Ceara, Natalia Sousa Freitas Queiroz, Aderson Omar Mourao Cintra Damiao

Summary: Therapeutic drug monitoring (TDM) is important in optimizing response to anti-tumor necrosis factor drugs and preventing inadequate drug exposure. This study aimed to describe the remission rates of Brazilian inflammatory bowel disease (IBD) patients at six months using a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels. The results showed that proactive TDM was associated with a high persistence rate of 82.9% and favorable remission rates at six months.

BIOMEDICINES (2023)

Article Cell Biology

Plasma Sphingomyelin Disturbances: Unveiling Its Dual Role as a Crucial Immunopathological Factor and a Severity Prognostic Biomarker in COVID-19

Diana Mota V. Toro, Pedro V. da Silva-Neto, Jonatan C. S. A. de Carvalho, Carlos A. M. Fuzo, Malena M. Perez, Vinicius E. Pimentel, Thais F. C. Fraga-Silva, Camilla N. S. R. Oliveira, Glaucia R. Caruso, Adriana F. L. Vilela, Pedro V. Nobre-Azevedo, Thiago V. Defelippo-Felippe, Jamille G. M. M. Argolo, Augusto M. Degiovani, Fatima M. R. Ostini, Marley R. S. Feitosa, Rogerio S. C. Parra, Fernando C. G. Vilar, Gilberto G. Gaspar, Jose J. R. da Rocha, Omar P. Feres, Gabriel P. Costa, Sandra R. C. Maruyama, Elisa M. S. Russo, Ana Paula M. Fernandes, Isabel K. F. M. Santos, Adriana T. Malheiro, Ruxana T. Sadikot, Vania L. D. Bonato, Cristina R. B. Cardoso, Marcelo Dias-Baruffi, Atila A. Trape, Lucia H. A. Faccioli, Carlos A. Sorgi, ImmunoCovid Consortium Grp

Summary: SARS-CoV-2 infection leads to distinct disease patterns with significant changes in host regulatory responses. Severe cases suffer from lung inflammation and systemic effects, while critically ill patients experience a lipid storm that affects inflammation and tissue damage. Sphingolipids play critical roles in various cellular processes and may serve as potential biomarkers and therapeutic targets for COVID-19.

CELLS (2023)

Article Gastroenterology & Hepatology

Vedolizumab in Mild-to-Moderate Crohn's Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study

Adriana Zanoni Dotti, Daniela Oliveira Magro, Eduardo Garcia Vilela, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Flavio Steinwurz, Marjorie Argollo, Nayara Salgado Carvalho, Jose Miguel Luz Parente, Murilo Moura Lima, Rogerio Serafim Parra, Ramir Luan Perin, Cristina Flores, Eloa Marussi Morsoletto, Sandro da Costa Ferreira, Juliano Coelho Ludvig, Roberto Luiz Kaiser, Mikaell Alexandre Gouvea Faria, Guilherme Mattioli Nicollelli, Adriana Ribas Andrade, Natalia Sousa Freitas Queiroz, Paulo Gustavo Kotze

Summary: This study demonstrates the effectiveness and safety of vedolizumab as a first-line biological agent in patients with mild-to-moderate Crohn's disease.

CROHNS & COLITIS 360 (2023)

Article Gastroenterology & Hepatology

Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study

Ramir Luan Perin, Daniela Oliveira Magro, Adriana Ribas Andrade, Marjorie Argollo, Nayara Salgado Carvalho, Aderson Omar Moura Cintra Damiao, Adriana Zanoni Dotti, Sandro da Costa Ferreira, Cristina Flores, Juliano Coelho Ludvig, Rodrigo Bremer Nones, Natalia Sousa Freitas Queiroz, Rogerio Serafim Parra, Flavio Steinwurz, Fabio Vieira Teixeira, Paulo Gustavo Kotze

Summary: The study demonstrated the efficacy and safety of tofacitinib in patients with ulcerative colitis from Latin America, which was consistent with previous studies from other countries and meta-analyses.

CROHNS & COLITIS 360 (2023)

No Data Available